This link will direct you to Mymetics' quoted Stock Price on NASDAQ's website.

Symbol................................................ Exchange........................................... Shares Outstanding......................... Market Cap (approx.)....................... 26-week Hi-Lo ($)............................. Ave. Trading Vol (approx.).............. Fiscal year-end.................................

MYMX OTCBB 190M 50M 0.36 - 0.10 80M december 31

Standard & Poor's Research
This link will direct you to Standard & Poor's Market Access coverage of Mymetics.

Christian J. F. Rochet CEO & President

Ernest Lübke Chief Financial Officer

Dr. Sylvain Fleury, PhD Chief Scientific Office

Anthony Jessop Vice President anthony.jessop@mymetics.com Tel: +1 303 800 6606

Investor Relations Anthony Jessop

Public Relations Anthony Jessop

This web site contains forward-looking statements that involve risks and uncertainties. The statements contained in this site that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those stated in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential", "continue", "possibly" or "clearly" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements, nor can we guarantee that our prototype vaccines will be proved effective under human clinical trials conditions. Moreover, neither we nor any other person assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after they have been disclosed, or to ensure such statements conform to actual results or to changes in our expectations.
Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in the Company's annual report on Form 10-K for the year ended December 31, 2003 and in our Registration Statement on Form S-1 dated May 22, 2002, as amended.